Clinical Trials

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT02884648 2026-02-06

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

35 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1 Recruiting

34 enrolled

Ovarian Neoplasms

NCT06580314 2026-01-14

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

880 enrolled

Ovarian Neoplasms

NCT07340164 2026-01-14

TROY

116 enrolled

Phase 1 Active not recruiting

Ovarian Neoplasms, Recurrence

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

352 enrolled

DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

38 enrolled

Ovarian Neoplasms

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

110 enrolled

DermatologicGynecologicHead & NeckSarcoma

Endometrial Neoplasms

NCT05039801 2025-10-14

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT07146919 2025-08-28

ANGELICA

87 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

37 enrolled

Advanced Ovarian Cancer

NCT06540729 2025-07-08

DAB

39 enrolled

Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Ovarian Neoplasms

NCT02873962 2025-06-08

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

73 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03694262 2025-05-30

EndoBARR

30 enrolled 7 charts

Phase 1/2 Not yet recruiting

Endometrial Neoplasms

NCT06990516 2025-05-25

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

90 enrolled

Ovarian Neoplasms

NCT04919629 2025-05-11

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

38 enrolled 12 charts

Endometrial Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT01220154 2025-02-21

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1 Completed

9 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06827353 2025-02-14

OVNI-B

Recruiting

300 enrolled

Carcinoma, Ovarian Neoplasms

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

614 enrolled

Ovarian Neoplasms

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

20 enrolled

Ovarian Cancer Recurrent

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

47 enrolled

Ovarian Neoplasms

NCT05183984 2024-10-16

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT04787289 2024-08-07

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

244 enrolled

Ovarian Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT03093155 2024-05-14

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

78 enrolled 18 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Terminated

9 enrolled 9 charts

BreastGastrointestinalGynecologicThoracic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

50 enrolled

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03476798 2024-02-15

Clovis-001

49 enrolled 13 charts

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT02399410 2024-01-30

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

GastrointestinalGynecologic

60 enrolled

Peritoneal Neoplasms, Colorectal Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

44 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04201561 2023-06-26

SELENIUM

Phase 3 Unknown

68 enrolled

BreastGastrointestinalGynecologicThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05819060 2023-04-19

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Phase 2 Unknown

44 enrolled

Ovarian Neoplasms

NCT01706120 2023-03-24

MITO16/MANGO-2

Phase 4 Unknown

400 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

Phase 3 Unknown

406 enrolled

Ovarian Neoplasms

NCT01097746 2022-10-28

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

33 enrolled 10 charts